Accumulated evidence has shown that FND triple-mutant AML represents a unique AML subset based on integrative genomic analysis and has an adverse prognosis (Ley et al., 2013; Papaemmanuil et al., 2016b). This evidence concerns the gene ALX3 and acute myeloid leukemia.